JPMA Suspends Vice Chairman Hasegawa’s Post For 6 Months On Promotion Conflict
This article was originally published in PharmAsia News
Executive Summary
Takeda President Yasuchika Hasegawa has been suspended from his JPMA vice chairman duties for six months because of inappropriate promotional activities Takeda carried out based on the CASE-J clinical trials for hypertension drug Blopress (ARB candesartan), the association announced on April 3.